Payment overview · 2025
General Payments
$238.16
13 reported records · 5 companies
Healthcare provider profile · identity verified
Johnathan W Lewis, MD
Allopathic & Osteopathic Physicians|Family Medicine · CAMDEN, AR · NPI 1699741298
Verified facts
What the public records show
CMS Open Payments records show Johnathan W Lewis, MD received $238.16 in general payments during 2025 across 13 reported records.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) accounted for 47.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Trelegy Ellipta.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 121 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 87 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 101 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $112.23 | 47.1% | 6 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $80.90 | 34.0% | 4 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $15.55 | 6.5% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $15.52 | 6.5% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $13.96 | 5.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $238.16 | 13 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $112.23 | 6 | 2025 |
Source payment records
|
|||||
| NUCALA Normalized: nucala |
Biological | GlaxoSmithKline, LLC. | $64.90 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $16.00 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $15.55 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $15.52 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $13.96 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $13.96 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 43 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 121 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
41 | 30 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
121 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
87 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
101 | 22 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 989 | 232 |
| Pantoprazole Sodium | Pantoprazole Sodium | 521 | 118 |
| Gabapentin | Gabapentin | 475 | 108 |
| Furosemide | Furosemide | 447 | 111 |
| Amlodipine Besylate | Amlodipine Besylate | 381 | 90 |
| Metoprolol Succinate | Metoprolol Succinate | 370 | 85 |
| Potassium Chloride | Potassium Chloride | 344 | 77 |
| Metoprolol Tartrate | Metoprolol Tartrate | 340 | 74 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 336 | 71 |
| Levothyroxine Sodium | Levothyroxine Sodium | 310 | 74 |
| Eliquis | Apixaban | 305 | 52 |
| Omeprazole | Omeprazole | 305 | 69 |
| Metformin Hcl | Metformin Hcl | 284 | 74 |
| Tamsulosin Hcl | Tamsulosin Hcl | 269 | 58 |
| Clopidogrel | Clopidogrel Bisulfate | 258 | 59 |
| Losartan Potassium | Losartan Potassium | 235 | 66 |
| Meloxicam | Meloxicam | 231 | 44 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 225 | 44 |
| Lisinopril | Lisinopril | 223 | 57 |
| Escitalopram Oxalate | Escitalopram Oxalate | 214 | 52 |
| Tramadol Hcl | Tramadol Hcl | 205 | 58 |
| Trazodone Hcl | Trazodone Hcl | 199 | 50 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 191 | 61 |
| Hydrochlorothiazide | Hydrochlorothiazide | 189 | 40 |
| Simvastatin | Simvastatin | 181 | 41 |
| Farxiga | Dapagliflozin Propanediol | 174 | 35 |
| Carvedilol | Carvedilol | 164 | 43 |
| Tizanidine Hcl | Tizanidine Hcl | 160 | 52 |
| Alprazolam | Alprazolam | 159 | 34 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 158 | 30 |
| Celecoxib | Celecoxib | 156 | 31 |
| Allopurinol | Allopurinol | 147 | 29 |
| Citalopram Hbr | Citalopram Hydrobromide | 139 | 26 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 130 | 34 |
| Sertraline Hcl | Sertraline Hcl | 123 | 25 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 121 | 20 |
| Oxycodone Hcl | Oxycodone Hcl | 119 | 16 |
| Duloxetine Hcl | Duloxetine Hcl | 118 | 21 |
| Aripiprazole | Aripiprazole | 107 | 20 |
| Hydralazine Hcl | Hydralazine Hcl | 103 | 24 |
| Ozempic | Semaglutide | 101 | 22 |
| Fluoxetine Hcl | Fluoxetine Hcl | 100 | 19 |
| Mirtazapine | Mirtazapine | 100 | 21 |
| Ezetimibe | Ezetimibe | 96 | 31 |
| Glipizide | Glipizide | 88 | 23 |
| Pravastatin Sodium | Pravastatin Sodium | 88 | 22 |
| Prednisone | Prednisone | 88 | 63 |
| Jardiance | Empagliflozin | 87 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 82 | 30 |
| Entresto | Sacubitril/Valsartan | 79 | 12 |
| Finasteride | Finasteride | 78 | 16 |
| Spironolactone | Spironolactone | 78 | 15 |
| Metformin Hcl Er | Metformin Hcl | 76 | 19 |
| Alendronate Sodium | Alendronate Sodium | 72 | 21 |
| Fenofibrate | Fenofibrate Nanocrystallized | 70 | 13 |
| Montelukast Sodium | Montelukast Sodium | 68 | 16 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 68 | 14 |
| Buspirone Hcl | Buspirone Hcl | 67 | 18 |
| Atenolol | Atenolol | 66 | 16 |
| Clonazepam | Clonazepam | 64 | 15 |
| Glimepiride | Glimepiride | 64 | 11 |
| Donepezil Hcl | Donepezil Hcl | 61 | 17 |
| Zolpidem Tartrate | Zolpidem Tartrate | 60 | 14 |
| Amitriptyline Hcl | Amitriptyline Hcl | 59 | 11 |
| Pregabalin | Pregabalin | 57 | 15 |
| Xarelto | Rivaroxaban | 57 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 54 | 24 |
| Valsartan | Valsartan | 54 | 14 |
| Diclofenac Sodium | Diclofenac Sodium | 52 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 52 | 15 |
| Levetiracetam | Levetiracetam | 52 | 13 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 52 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 50 | 17 |
| Paroxetine Hcl | Paroxetine Hcl | 47 | 11 |
| Glipizide Er | Glipizide | 46 | suppressed |
| Baclofen | Baclofen | 45 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 44 | 11 |
| Amoxicillin | Amoxicillin | 44 | 41 |
| Warfarin Sodium | Warfarin Sodium | 44 | suppressed |
| Mounjaro | Tirzepatide | 43 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 42 | suppressed |
| Lansoprazole | Lansoprazole | 42 | suppressed |
| Risperidone | Risperidone | 42 | suppressed |
| Bumetanide | Bumetanide | 41 | suppressed |
| Fluconazole | Fluconazole | 41 | 20 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 41 | 30 |
| Chlorthalidone | Chlorthalidone | 40 | suppressed |
| Linzess | Linaclotide | 40 | suppressed |
| Naproxen | Naproxen | 40 | suppressed |
| Verapamil Er | Verapamil Hcl | 40 | suppressed |
| Irbesartan | Irbesartan | 38 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 38 | 20 |
| Diazepam | Diazepam | 37 | suppressed |
| Temazepam | Temazepam | 37 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 36 | 36 |
| Divalproex Sodium | Divalproex Sodium | 36 | suppressed |
| Lorazepam | Lorazepam | 35 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 34 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 34 | 11 |
| Dilt-Xr | Diltiazem Hcl | 33 | suppressed |
| Fenofibrate | Fenofibrate | 33 | suppressed |
| Januvia | Sitagliptin Phosphate | 33 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 33 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 30 | 11 |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 30 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 30 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 30 | suppressed |
| Estradiol | Estradiol | 30 | suppressed |
| Topiramate | Topiramate | 30 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 29 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 29 | suppressed |
| Azithromycin | Azithromycin | 28 | 27 |
| Morphine Sulfate Er | Morphine Sulfate | 28 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 27 | 23 |
| Clonidine Hcl | Clonidine Hcl | 27 | 13 |
| Doxycycline Hyclate | Doxycycline Hyclate | 27 | 14 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 27 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 27 | 11 |
| Sucralfate | Sucralfate | 27 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 26 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 26 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Klor-Con M20 | Potassium Chloride | 25 | suppressed |
| Methylprednisolone | Methylprednisolone | 25 | 25 |
| Metolazone | Metolazone | 25 | 11 |
| Oxycontin | Oxycodone Hcl | 25 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 25 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 25 | 21 |
| Ibandronate Sodium | Ibandronate Sodium | 24 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Acyclovir | Acyclovir | 23 | suppressed |
| Bupropion Xl | Bupropion Hcl | 23 | suppressed |
| Digoxin | Digoxin | 23 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 23 | suppressed |
| Famotidine | Famotidine | 23 | suppressed |
| Nifedipine Er | Nifedipine | 23 | suppressed |
| Ramipril | Ramipril | 23 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 23 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 23 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 22 | suppressed |
| Methocarbamol | Methocarbamol | 22 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 21 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 21 | suppressed |
| Brilinta | Ticagrelor | 20 | suppressed |
| Novolin R | Insulin Regular, Human | 20 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 20 | suppressed |
| Torsemide | Torsemide | 20 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 20 | suppressed |
| Mupirocin | Mupirocin | 19 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 18 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 18 | suppressed |
| Ibuprofen | Ibuprofen | 18 | suppressed |
| Latanoprost | Latanoprost | 18 | suppressed |
| Levofloxacin | Levofloxacin | 18 | 12 |
| Nitroglycerin | Nitroglycerin | 18 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 18 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 18 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 17 | suppressed |
| Ketoconazole | Ketoconazole | 17 | suppressed |
| Lamotrigine | Lamotrigine | 17 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 17 | suppressed |
| Nystatin | Nystatin | 17 | suppressed |
| Cephalexin | Cephalexin | 16 | suppressed |
| Fentanyl | Fentanyl | 16 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 16 | suppressed |
| Olanzapine | Olanzapine | 16 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 16 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 16 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 15 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 14 | suppressed |
| Memantine Hcl | Memantine Hcl | 14 | suppressed |
| Ondansetron Odt | Ondansetron | 14 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 14 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 13 | suppressed |
| Clonidine | Clonidine | 13 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 13 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Carbamazepine | Carbamazepine | 12 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Klor-Con M10 | Potassium Chloride | 12 | suppressed |
| Methotrexate | Methotrexate Sodium | 12 | suppressed |
| Myrbetriq | Mirabegron | 12 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $238.16 · 13 records | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA, MOUNJARO, NUCALA, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, Wegovy, ZEPBOUND | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error